Multicenter Evaluation of Memory Remediation in Traumatic Brain Injury With Donepezil: A Randomized Controlled Trial
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Memory impairments are common chronic and functionally important consequences of traumatic brain injury (TBI). Among patients with persistent verbal memory impairments due to TBI-related cholinergic deficits, donepezil (an acetylcholinesterase inhibitor) may improve these and related problems. The Multicenter Evaluation of Memory Remediation in TBI with Donepezil (MEMRI-TBI-D) study, a four-site, randomized, parallel-group, double-blind, placebo-controlled, 10-week clinical trial, evaluated the efficacy of donepezil on verbal memory impairments, co-occurring cognitive and noncognitive neuropsychiatric problems, and functional status among persons with severe, persistent, and functionally limiting verbal memory problems at least 6 months after mild, moderate, or severe TBI. Efficacy, safety, and tolerability measures were assessed. Seventy-five participants were randomly assigned to donepezil (N=37) and placebo (N=38) groups. In both modified intent-to-treat and per-protocol analyses, donepezil significantly improved memory (i.e., verbal learning, as measured by the Hopkins Verbal Learning Test-Revised Total Trials 1-3, the primary outcome measure) when compared with placebo. Treatment-responder rates in the donepezil and placebo groups were 42% and 18%, respectively, yielding a number needed to treat of 3.5. Among donepezil responders, delayed recall and processing speed also improved significantly. Treatment-emergent adverse event rates for donepezil and placebo were 46% and 8%, respectively, and mild or moderate (85%); diarrhea and nausea were significantly more common in the donepezil group, yielding a number needed to harm of 6.25 and a likelihood to be helped or harmed ratio of 1.79. These results suggest that donepezil is an efficacious treatment for severe, persistent memory impairments after predominantly severe TBI, with a relatively favorable safety and tolerability profile.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Multicenter Evaluation of Memory Remediation in Traumatic Brain Injury With Donepezil: A Randomized Controlled Trial
- Date Crossref
- 01/04/2025
- Éditeur
- American Psychiatric Association Publishing
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Memorial Hermann Institute for Rehabilitation and Research Foundation pays non établi dans la noticeÉtablissement de santé
-
Craig Hospital Research Department pays non établi dans la noticeÉtablissement de santé
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Thomas Jefferson University Department of Rehabilitation Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Spaulding Rehabilitation Hospital Department of Physical Medicine and Rehabilitation pays non établi dans la noticeÉtablissement de santé
-
Moss Rehabilitation Hospital pays non établi dans la noticeÉtablissement de santé
-
Rehabilitation Hospital of Indiana pays non établi dans la noticeÉtablissement de santé
-
Indiana University School of Medicine Department of Physical Medicine and Rehabilitation pays non établi dans la noticeUniversité ou école supérieure
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
University of Colorado Denver pays non établi dans la noticeUniversité ou école supérieure
-
University of Colorado School of Medicine Department of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
Brain Injury Research Center pays non établi dans la noticeStructure de recherche
Memorial Hermann Institute for Rehabilitation and Research Foundation, Research Department — Craig Hospital et Harvard University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.